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Endothelial cellsReports on the role of AMP-activated protein kinase (AMPK) in thrombin-mediated activation of endothelial
nitric-oxide synthase (eNOS) in endothelial cells have been conﬂicting. Previously, we have shown that under
culture conditions that allow reduction of ATP-levels after stimulation, activation of AMPK contributes to eNOS
phosphorylation and activation in endothelial cells after treatmentwith thrombin. In this paperwe examined the
signaling pathways mediating phosphorylation and activation of eNOS after stimulation of cultured human
umbilical vein endothelial cells (HUVEC)with histamine and the role of LKB1-AMPK in the signaling. InMorgan's
medium 199 intracellular ATP was lowered by treatment with histamine or the ionophore A23187 while in
mediumRMPI 1640 ATPwas unchanged after identical treatment. Inmedium 199 inhibition of Ca+2/CaMkinase
kinase (CaMKK) by STO-609 only partially inhibitedAMPK phosphorylation but after gene silencing of LKB1with
siRNA therewas a total inhibition of AMPK phosphorylation by STO-609 after treatmentwith either histamine or
thrombin, demonstrating phosphorylation of AMPK by both upstream kinases, LKB1 and CaMKK. Down-
regulationofAMPKwith siRNApartially inhibited eNOSphosphorylation causedbyhistamine in cellsmaintained
in medium 199. Downregulation of LKB1 by siRNA inhibited both phosphorylation and activity of eNOS and
addition of the AMPK inhibitor Compound C had no further effect on eNOS phosphorylation.When experiments
were carried out in medium 1640, STO-609 totally prevented the phosphorylation of AMPK without affecting
eNOS phosphorylation. AMPKα2 downregulation resulted in a loss of the integrity of the endothelial monolayer
and increased expression of GRP78, indicative of endoplasmic reticular (ER) stress. Downregulation of AMPKα1
had no such effect. The results show that culture conditions affect endothelial signal transduction pathways after
histamine stimulation. Under conditions where intracellular ATP is lowered by histamine, AMPK is activated by
both LKB1 and CaMKK and, in turn, mediates eNOS phosphorylation in an LKB1 dependent manner. Both
AMPKα1 and −α2 are involved in the signaling. Under conditions where intracellular ATP is unchanged after
histamine treatment, CaMKK alone activates AMPK and eNOS is phosphorylated and activated independent of
AMPK.AMPK, AMP-activated protein
helial NO-synthase; ER stress,
al vein endothelial cells; NO,
active oxygen species; VEGF,
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Because of its unique location the endothelial layer is constantly
exposed to a variety of stimulatory interactions, physical, humoral and
cellular. The transduction of these signals is critical for an appropriate
cellular response while derailment of the signaling can be a key
feature of a pathologic response or disease [1]. One of the crucialresponses to a variety of signals is the production of nitric-oxide (NO)
from arginine through the activation of endothelial NO-synthase
(eNOS) [2]. While a complex network of pathways, numerous kinases
and many phosphorylation sites are involved in the regulation of
eNOS activity, phosphorylation at the most thoroughly studied site at
Ser1177 is generally found to be a critical requirement for eNOS
activation [3]. The best characterized pathway mediating this
phosphorylation is the phosphatidylinositol 3-kinase (PI3K)–Akt
cascade [4,5]. However, eNOS phosphorylation by AMPK has been
observed in a variety of conditions e.g. after treatment with AICAR [6],
metformin [7], PPAR agonists [8], adiponectin [9], VEGF [10] or ICAM-
1 [11] and under hypoxic conditions [12]. While the role of AMPK as a
metabolic masterswitch has been well established in tissues such as
the skeletal and cardiac muscle its precise role in endothelial cell
metabolism is less well understood [13]. It has been suggested that
endothelial cells exist in a permanent state of “metabolic hypoxia”
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role in the maintenance of endothelial function and in affecting
signaling cascades than as an intracellular fuel gauge [13].
We have previously reported that in primary cultures of human
umbilical vein endothelial cells (HUVEC) thrombin stimulates eNOS
phosphorylation at Ser 1177 via a pathway that is partly dependent on
AMPK [15] but independent of PI3K-Akt [16]. This was demonstrated
both by using an inhibitor of AMPK (Compound C) and by gene
silencing of both α1 and α2 isoforms of AMPK by siRNA which also
caused a reduction in eNOS activity. However, this pathway was only
activated under culture conditions that allowed a sharp but brief fall
in cellular ATP after thrombin stimulation (Morgan's medium 199).
Under culture conditions that prevented or did not allow such a fall in
the energy stores of the cells (medium RPMI 1640) AMPK was still
activated but exclusively via a different upstream pathway (CaMKK-
mediated activation of AMPK) and downstream this activation of
AMPK played no role in the activation of eNOS. Thus, after thrombin
stimulation of HUVEC we found both AMPK-dependent and AMPK-
independent stimulation of eNOS. The mechanism of the AMPK-
independent eNOS activation after thrombin treatment, seems to be
identical to that reported by Stahmann et al. [17] using similar culture
conditions as those not allowing ATP fall after stimulation. However,
under those same culture conditions, energy deprivation by 2-deoxy-
glucose resulted in an activation of the AMPK-eNOS pathway after
stimulation with thrombin [15]. Hypoxia, which presumably causes
ATP depletion, has also been shown to cause AMPK-dependent eNOS
phosphorylation (activation) [12]. Most recently, however, it has been
demonstrated that VEGF activates AMPK via a Ca+2/CaMKKβ-
dependent pathway and that the VEGF-stimulated eNOS activation
is independent ofAMPKevenwhenVEGF treatment is combinedwith2-
deoxy-glucose to cause energy deprivation [18]. In contrast to thrombin
or histamine, VEGF activates eNOS via a PI3K-Akt dependent pathway
althoughAMPKmediated eNOSphosphorylationhas also been reported
after VEGF treatment [10].
The upstream AMPK kinase mediating the AMPK activation that
takes place when ATP falls is not known but has been presumed to be
LKB1 [19]. In this paper, using gene silencing by siRNA, we provide
direct evidence that LKB1 is necessary for the stimulation of the
AMPK-dependent pathway of eNOS activation that partly mediates
the NO-response to thrombin stimulation under conditions allowing a
fall in cellular ATP levels. Furthermore, we show that this pathway is
also activated by histamine, another agonist binding to a G-protein
linked receptor on the endothelial surface, as well as by the Ca+2-
ionophore A23187 which also mediates reduction in ATP-levels.
We also show that downregulation of the α2 isoform of AMPK
resulted in a loss of the integrity of the endothelial monolayer possibly
linked to endoplasmic reticular (ER) stress whereas downregulation
of the other isoform, α1, had no such effect. Thus, the importance of
α2 is further emphasized although the α1 isoform is expressed to a
greater extent in HUVEC than the α2 isoform.
2. Materials and methods
2.1. Materials
EBM-2 was purchased from Clonetics. Other cell culture media,
Foetal Bovine Serum and Penicillin-Streptomycin were purchased
from Gibco Brl, Life Technologies. Tissue culture plates (35 mm) and
ﬂasks (50 mL) were from Nunc, Cryotin X (trypsin) from cod was
provided by The Science Institute of Iceland. Thrombin, histamine,
A23187, Tempol and Trypsin-EDTA Solution were purchased from
Sigma. STO-609 and Compound C were from Calbiochem. Hybond ECL
Nitrocellulose membrane (6×8 cm), ECL+PLUS Western blotting
detection system and Hyperﬁlm ECL High performance chemilumi-
nescence ﬁlm were from Amersham Pharmacia Biotech. Cyclic GMP
XP Assay kit and antibodies against eNOS, phospho-eNOS (Ser1177),AMPK, phospho-AMPK (Thr172), AMPKα1, AMPKα2, LKB1, phospho-
LKB1, GRP78, p47phox, Pan-Actin and Anti-Rabbit IgG/HRP-linked
came from Cell Signaling Technology. Antibodies against ACC and
phospho-ACC (Ser79) were from Upstate. Lipofectamine™ RNAiMAX
Reagent and 5-(and 6)-carboxy-2′7′ dichlorodihydoﬂuorescein dea-
cetate (carboxy-H2DCFDA) were from Invitrogen. Validated siRNA
against AMPKα1 (s100), AMPKα2 (s11057) and LKB1 (s13580) came
from Ambion as well as a negative control siRNA (Silencer Negative
Control #1 with a sequence that does not target any gene product).
Eliten kit was purchased from Promega. gp91phox antibody came from
Santa Cruz.
2.2. Cell culture
Endothelial cells were cultured from human umbilical veins by a
modiﬁcation of the method of Jaffe et al. as previously reported [20].
The cells were harvested by Cryotin X trypsin digestion and seeded on
35 mm culture dishes in Morgan's medium 199 containing 20% foetal
bovine serum and antibiotics (penicillin, 100 units/mL and strepto-
mycin, 100 μg/mL). The culture dishes were incubated at 37 °C in
humidiﬁed air with 5% CO2. The medium was changed 24 h after
seeding the cells and then every 2–3 days thereafter until the cell
culture reached conﬂuence (after ~7 days).
When conﬂuent the cells were washed with the appropriate
medium and placed in 1.0 mL serum free medium with or without
inhibitors at the indicated concentrations. Agonist was added 10 to
20 min later in a concentration calculated to reach the intended
concentration for each experiment and left on for additional 2 to
3 min. The agonists were then removed along with the medium and
cellular reactions terminated by adding 250 μL SDS sample buffer. The
samples were boiled for 5 min and centrifuged for 10 min at 3000 rpm.
The samples were then ready to be either used or stored at−20 °C.
2.3. siRNA transfection
Endothelial cells, grown to approximately 80% conﬂuence in
25 cm2 tissue culture ﬂasks, were trypsinized and diluted sixfold on
to 35 mm culture dishes. 24 h later, the cells were transfected with
Lipofectamine™ RNAiMAX transfecting agent containing siRNA for
AMPKα1, AMPKα2 or LKB1 (20nM) in an antibiotics-free EBM-2
medium containing 6% serum. Cells were cultured for 44–48 h and
protein expression analyzed by Western blotting.
2.4. Electrophoresis and immunoblotting
Samples (8 μL) were resolved by SDS-PAGE (10%). The gels were
blotted and the proteins thereby transferred to nitrocellulose. The
membranes were hybridized with the indicated antibodies and
subsequently with a secondary antibody (Anti-Rabbit IgG/HRP-
linked). The immuno-complexes were detected with ECL+PLUS
Western blotting detection system and developed onto a ﬁlm. Equal
loading was ascertained by hybridizing membranes with antibodies
against unphosphorylated protein. The band intensity was quantiﬁed
using Kodak 3.5 software.
2.5. Measurement of ATP
ATP was determined by luciferase assay. For validation HPLC was
used in which case AMP was also determined (data not shown). For
ATP determination using the luciferase assay the medium was
removed from the cells and the cells lyzed by adding 0.5 mL of 0.5 N
perchloric acid. After 30 min a 10 μL sample was diluted ×100 in
water mixed with 80 μL of a luciferase mixture from an Eliten kit by
Promega.
Fig. 1. Effects of histamine or ionophore on ATP levels in different media. Comparison
between the effects of 3 minute treatment with histamine (10 μM) and A23187
(0.6 μM) on ATP levels of cells in medium 199 or 1640. Effects of 2-deoxy-glucose
treatment (20 mM, 7 min) on ATP levels in cells maintained in medium 1640. Results
are expressed as % lowering of ATP level relative to control (unstimulated cells) and
show the average±S.D. of at least three independent experiments each done in
duplicate. (†ns/*pb0.001/**pb0.05 vs control).
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Cells were treated with siRNA for AMPKα1 or−α2 as described in
Section 2.3 with or without the indicated inhibitor. After 67 h of
treatment with siRNA the cells were washed with medium 199
without serum and placed in thatmedium for additional 30 min, again
with or without an inhibitor. Cell morphology was monitored with
confocal microscopy and photographic images obtained at the
indicated intervals using Leica DFC310 FX.
2.7. Determination of ROS levels
For determination of ROS levels, cells were washed twice with PBS
and incubated with 10 μM carboxy-H2DCFDAwhich is taken up by the
cells and cleaved by intracellular esterases and transformed to a
ﬂuorescent dye when oxidized. After 15 min the cells were trypsi-
nized and ﬂuorescence analyzed by ﬂow cytometry.
2.8. cGMP measurements
HUVEC monolayers were washed with Morgan's medium 199 or
medium1640 and placed in 1.0 mL Morgan's medium 199 or medium
1640 containing 0.25 mM IBMX. The cells were incubated for 17 min.
at 37 °C. Histamine was then added to give a ﬁnal concentration of
10 μM and the cells further incubated for 3 min. The reaction was
stopped by removing the medium and adding 0.5 mL of 0.1 M HCl.
Intracellular cGMP was determined using an enzyme immunoassay
kit in accordance with the manufacturer's instructions.
2.9. Statistical analysis
Values are expressed as average±S.D. Unpaired, two-tailed
Student's t-test was performed for comparisons between groups.
The level of signiﬁcance was set at pb0.05. Software used was
GraphPad Prism 5.00.
3. Results
3.1. The effects of histamine or A23187 on intracellular ATP in different
media
To investigate the upstream mechanisms of AMPK activation after
treatmentwith histamine or theCa+2-ionophoreA23187,wemeasured
the levels of intracellular ATP after stimulation (Fig. 1). In medium 199,
treatment with histamine (10 μM, 3 min.) lowered intracellular ATP by
8±1%. Treatmentwith the ionophore A23187 (0.6 μM, 3 min.) lowered
intracellularATPby53±3%. Inmedium1640, the effects of histamineor
A23187 on ATP was negligible (1±4% increase and 2±4% lowering,
respectively). After 2-deoxy-glucose (20 mM, 7 min.) had been added
to medium 1640 intracellular ATP was lowered by 7±2%.
3.2. The effects of histamine or A23187 on AMPK phosphorylation — role
of the upstream kinases LKB1 and CaMKK
Inmedium199, both histamine andA23187 caused phosphorylation
of AMPK that was partly inhibited by the CaMKK inhibitor STO-609,
histamine stimulation by 76±4% and A23187 stimulation by 14±5%
(Fig. 2A). In culturemedium1640, the phosphorylation of AMPK caused
by these agonists was totally inhibited by STO-609 (105±3% for
histamine, 102±2% for A23187) (Fig. 2A). After LKB1 downregulation
there was a complete inhibition of histamine or thrombin mediated
phosphorylation of AMPK by STO-609 in cells maintained in culture
medium 199 (95±5% and 102±4%, respectively) (Fig. 2B). Similar
response was found after stimulationwith the Ca+2-ionophore A23187
(data not shown). In contrast, in cells treatedwith control siRNA, AMPK
phosphorylation after histamine or thrombin was partly inhibited bySTO-609 (67±2% and 72±3%, respectively). As shown in Fig. 2C, LKB1
downregulation greatly reduced LKB1 expression without affecting
AMPK expression (Fig. 2C).
To test the role of the two upstream AMPK kinases in the basal
phosphorylation of AMPK, we measured AMPK phosphorylation in
unstimulated cells treated with STO-609 or siRNA for LKB1 (Fig. 2C).
In medium 199, downregulation of LKB1 lowered the basal phos-
phorylation of AMPK by 66±8% whereas pretreatment with STO-609
had no effect. In medium 1640, AMPK phosphorylation was
unaffected by these manipulations (not shown). Treatment of cells
with control siRNA had no effect on basal AMPK phosphorylation
(Fig. 2B) and LKB1expression was unaffected by treatment with
AMPKα1 and/or −α2 siRNA (Fig. 3B).
To test the role of LKB1 phosphorylation in the response to
histamine and thrombin we compared the phosphorylation of LKB1 at
Ser428 inmedium 199 and inmedium 1640. As shown in Fig. 2D, both
agonists caused similar phosphorylation of LKB1 at Ser428 in the two
media.
3.3. The involvement of AMPK in eNOS phosphorylation after histamine
Histamine caused phosphorylation of eNOS in both media.
However, in medium 199, simultaneous downregulation of AMPKα1
and −α2 by siRNA partially inhibited the phosphorylation of eNOS
after treatmentwith histamine (51±3% inhibition)whereas the same
treatment had no effect in medium 1640. Downregulation of either
AMPKα1 or−α2 separately had a nonsigniﬁcant effect in both media
(Fig. 3A). Western blots showing speciﬁc siRNA knockdown of each
isoform as well as an unchanged expression of LKB1 is demonstrated
in Fig. 3B. Pretreatment with STO-609 (an inhibitor of AMPK as well as
CaMKK [21]) partially inhibited histamine stimulated eNOS phos-
phorylation in medium 199 (42±2% inhibition) compared to
no effects in medium 1640 (4±4% inhibition) (Fig. 3C). However,
when cellular ATP was lowered by pretreatment with 2-deoxy-
glucose, STO-609 inhibited histamine stimulated eNOS phosphoryla-
tion by 35±2% in medium 1640, further supporting the partial
contribution of AMPK in eNOS phosphorylation after histamine
stimulation in cells where intracellular ATP is lowered. Interestingly,
phosphorylation of ACC after histamine treatment (Fig. 3D) was
largely inhibited in medium 199 after downregulation of AMPKα2 by
siRNA (105±51%), compared to the insigniﬁcant effect of AMPKα1
Fig. 2. The role of CaMKK and LKB1 in histamine, thrombin or ionophore mediated phosphorylation of AMPK and in basal phosphorylation of AMPK in different media. (A) The effects
of 20 minute pre-treatment with STO-609 (10 μM) on AMPK phosphorylation (Thr172) in medium 199 or 1640 after treatment with histamine (10 μM, 2 min) or A23187 (0.6 μM,
2 min). (B) The effects of STO-609 on AMPK phosphorylation in cells in medium 199, pretreated with siRNA for LKB1 (20 nM) or control siRNA (20 nM) and then stimulated with
histamine or thrombin (1 U/mL, 2 min). (C) The effects of STO-609 or LKB1 downregulation by siRNA on basal phosphorylation of AMPK in medium 199. Basal phosphorylation of
AMPK in cells treated with control siRNA is shown in 2B. (D) Thrombin or histamine mediated phosphorylation of LKB1 (Ser428) in cells in either medium 199 or 1640. Conﬂuent
endothelial cells were stimulated as indicated, lysates were electrophorized and blotted as described in “Methods” and detected using antibodies against AMPK, Thr172
phosphorylated AMPK, LKB1 or Ser428 phosphorylated LKB1. The results are expressed as a ratio of phospho-AMPK:total AMPK or phospho-LKB1:total LKB1 relative to control and
show the average±S.D. of at least three independent experiments. (†ns/#pb0.001/*pb0.01/**pb0.05 vs untreated cells, ††ns vs cells without siRNA).
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isoforms were not detected in medium 1640 where downregulation
of either AMPKα1 or −α2 separately had little or no effects on ACC
phosphorylation after histamine (−1±3% and −7±9% inhibition
respectively). Downregulation of both AMPK isoforms simultaneously
caused a total inhibition of ACC phosphorylation after histamine
treatment both in medium 199 and 1640 (109±36% and 115±19%
inhibition, respectively). Negative control siRNA had no effect on ACC-
phosphorylation (not shown).3.4. The role of LKB1 in the phosphorylation and activation of eNOS
As demonstrated previously, eNOS phosphorylation after hista-
mine stimulation is partly dependent on AMPK under conditions
where intracellular ATP is lowered by histamine treatment (Fig. 3A).
AMPK phosphorylation is then mediated by both LKB1 and CaMKK
(Fig. 2B). Downregulation of LKB1 reduced histamine induced eNOS
phosphorylation by 64±5% whereas control siRNA had no effect (not
shown). Also, in cells treated with siRNA for LKB1, pretreatment with
Fig. 3. The role of the two AMPKα isoforms in histamine mediated phosphorylation of eNOS and ACC in different media. (A) The effects of AMPKα1 and/or−α2 siRNA (20 nM) on
eNOS phosphorylation (Ser1177) after treatment with histamine (10 μM, 3 min) in medium 199 or 1640. The results are normalized to the effects of histamine in cells maintained in
199 without siRNA treatment. (B) The effect of siRNA for AMPKα1 and/or−α2 on the expression of both AMPKα isoforms and LKB1 in HUVEC. (C) The effects of 20 minute pre-
treatment with STO-609 (10 μM) on eNOS phosphorylation caused by histamine in medium 199, 1640 or 1640 with added 2-deoxy-glucose (2-DG) (20 mM, 7 min). The results are
normalized to the effects of histamine alone in eachmedium. (D) The effects of AMPKα1 and/or−α2 siRNA (20 nM) on ACC phosphorylation (Ser79) after treatment with histamine
(10 μM, 3 min) in medium 199 or 1640. The results are normalized to the effects of histamine in cells without siRNA treatment in both media. Cells were treated as described in
“Methods” and results in A, C and D expressed as a ratio of phospho-eNOS:total eNOS or phospho-ACC:Actin relative to cells stimulated with histamine. Phosphorylation of control
cells has been subtracted from all values causing some ratios to fall below zero. Results show the average±S.D. of at least three independent experiments. (†ns/*pb0.05/**pb0.01/
#pb0.001 vs cells treated with histamine alone).
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eNOS phosphorylation by histamine in medium 199 (Fig. 4A).
Treatment with control siRNA did not change the inhibitory effects
of STO-609 or Compound C on eNOS phosphorylation after histamine
(55±2% and 61±10% inhibition, respectively) (Fig. 4A). Thus, the
results show that the histamine induced phosphorylation of eNOS
mediated by AMPK is dependent on LKB1. Finally, to test for
involvement of LKB1 in NO-production, we determined cGMP levels
after histamine treatment. In cells treated with LKB1 speciﬁc siRNA,
there was a 46±10% reduction in the accumulation of cGMP afterhistamine stimulation, similar to the response in cells maintained in
medium 1640 (Fig. 4B).
3.5. The role of AMPKα2 in maintaining endothelial monolayer integrity
Although AMPKα1 is expressed to a much greater extent in
endothelial cells than the α2 isoform [15,22], the importance of the
latter is not only manifested in the effects of AMPKα2 downregulation
by siRNA on ACC phosphorylation but also by marked effects of
AMPKα2 downregulation by siRNA on the morphology of the cell
Fig. 4. The role of LKB1 in histamine mediated phosphorylation and activation of eNOS
in medium 199. (A) The effects of 20 minute pretreatment with STO-609 (10 μM) or
Compound C (10 μM) on histamine (10 μM, 3 min) mediated eNOS phosphorylation
(Ser1177) in LKB1 downregulated cells (20 nM) or cells treated with control siRNA
(20 nM). Cells were treated as described in “Methods”. Results are normalized to the
response to histamine alone either in cells pretreated with LKB1 or control siRNA and
show the average±S.D. of at least three independent experiments. (†ns/*pb0.001/
**pb0.01 vs cells treated with histamine alone). (B) Cells were stimulated by histamine
(10 μM, 10 min) in medium 199 or 1640. LKB1 was downregulated in medium 199
using LKB1 speciﬁc siRNA (20 nM). Intracellular cGMP was determined using an
enzyme immunoassay kit as described in “Methods”. The results are expressed as
percent of the response to histamine in medium 199 without siRNA pre-treatment and
show the average±S.D. of four independent experiments each done in duplicate. (†ns/
*pb0.01 vs cells treated with histamine in medium 199).
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and then transferred to serum free media for up to 30 min. This
resulted in deterioration of monolayer integrity in cells lacking
AMPKα2, with shrinkage of the cells and loss of contact both between
cells and with the culture substrate (Fig. 5A). Cells lacking the α1
isoform showed no morphological changes nor did control cells (not
treated with siRNA). Treatment of the AMPKα2 downregulated cells
with the SOD-mimetic Tempol markedly inhibited these morphologic
changes. Downregulation of LKB1 did not affect the morphology (not
shown). As shown in Fig. 5B the expression of the chaperone GRP78,
an indicator of ER stress, was greatly enhanced after downregulation
of AMPKα2 whereas downregulation of AMPKα1 had no such effect.
Treatment with Tempol prevented the increase of GRP78 expressionin cells treated with AMPKα2 siRNA. Downregulation of either
AMPKα1 or AMPKα2 but not LKB1 increased the level of reactive
oxygen species (ROS) as measured by DCF ﬂuorescence (Fig. 5C). The
increase in ROS levels in AMPKα downregulated cells was not affected
by treatment with Tempol. AMPKα1 or−α2 downregulation had no
effect on the expression of the p47phox subunit of NADPH-oxidase
(Fig. 5D) nor the expression of the gp91phox subunit (data not shown).
4. Discussion
The heterotrimeric serine/threonin protein kinase AMPK main-
tains the balance between cellular ATP production and consumption
and has been described as a “metabolic masterswitch” [23]. In
endothelial cells, AMPK is activated by a variety of stimuli only
some of which cause changes in the energy level of the cell [13]. While
several studies have described phosphorylation of Ser1177 on eNOS
by AMPK [6–12], other studies have disassociated AMPK activation
from eNOS phosphorylation and activation [13,24].
In this study we found that in endothelial cells stimulated by
histamine, culture conditions dictate which signal transduction
pathways are activated. Under conditions where intracellular ATP is
lowered after histamine stimulation, AMPK is activated by two
upstream kinases, LKB1 and CaMKK, and in turn, mediates eNOS
phosphorylation. Under conditions not facilitating ATP-lowering after
histamine treatment AMPK is still activated, but only via the CaMKK
pathway, and downstream, this AMPK-activation played no role in the
phosphorylation of eNOS and therewasmuch less NO-production.We
have previously demonstrated a similar response in cells treated with
thrombin [15]. It has been presumed that LKB1 is the upstream AMPK
kinase mediating AMPK activation when ATP falls after stimulation. In
this paper, using the gene silencing of LKB1 by siRNA, we directly
demonstrate how LKB1 contributes to the AMPK dependent pathway
of eNOS phosphorylation after treatment with the G-protein activat-
ing agonists histamine and thrombin as well as by the Ca+2-
ionophore A23187.
The activation of AMPK requires the phosphorylation of threonine
172 (Thr172) within the α catalytic subunit mediated by one or more
upstream kinases (AMPKK) [23]. In mammals, two kinases have been
identiﬁed as physiological kinases upstream of AMPK. These are LKB1
[19] and CaMKK [25] although Tak1 (transforming growth factor-
beta-activated kinase) has been shown to phosphorylate and activate
AMPK in a cell free system [26]. Additionally, in epithelial cells, TAK1
has been shown to activate AMPK independently of LKB1 or CaMKK
[27]. The phosphorylation of AMPK Thr172 is reversible and the
phosphatase PP2Cα is suggested to play a major role in the regulation
of AMPK activity [28].
Recently, it has been demonstrated that AMP does not directly
activate LKB1 [29] or CaMKK [25] or promote phosphorylation of
AMPK by these upstream kinases [28]. A new model proposes two
distinct mechanisms for AMP-mediated activation of AMPK, i.e. by a
direct allosteric activation and by protection from phosphatases
[28,30]. This model assumes that AMPK is phosphorylated by a Ca+2-
activated pathway dependent on CaMKK, and an AMP-dependent
pathway, mediated by LKB1. The phosphorylating and activating
effects of the constitutively active LKB1 on Thr172would, according to
this model, increase when the level of intracellular AMP rises and
inhibits Thr172 dephosphorylation by phosphatases [28]. Conversely,
since CaMKK requires a Ca+2 signal for activation which in turn
causes phosphorylation of AMPK, this pathway is not dependent on
AMP, as demonstrated by Stahmann and others [17,31]. Our ﬁndings
that the basal phosphorylation of AMPK in endothelial cells is
mediated by LKB1 without a contribution of CaMKK (Fig. 2C) is in
concordance with this model.
The contribution of AMPK in mediating thrombin induced
phosphorylation and activation of eNOS was originally discovered
when it was realized that thrombin reduced basal phosphorylation of
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stimulating eNOS phosphorylation [32]. These experiments were
carried out on HUVEC maintained in culture medium 199. Subse-
quently, Stahmann and coworkers showed total inhibition of
thrombin mediated phosphorylation of AMPK by inhibiting the
upstream kinase CaMKK by STO-609 [17]. Furthermore, in their
system, they convincingly showed that eNOS phosphorylation by
thrombin was not mediated by AMPK since inhibition of CaMKK or
AMPK or their downregulation by siRNA had no effects on eNOS
phosphorylation or NO-production, seemingly contradicting our
previous ﬁndings. When we repeated our experiments in culture
medium 1640 orWilliams medium our results were identical to those
of Stahmann and coworkers. The reconciliation came through the
demonstration that thrombin stimulation of endothelial cells differ-
entially affected cellular ATP levels, depending on the culture medium
used. In culture medium 199 there is a fall in ATP after stimulation by
thrombin [15] and, as shown in this paper, also after histamine as well
as the ionophore A23187. In culturemedium 1640 there is no such fall
in ATP after stimulation with any of these agonists. As we previously
showedwith thrombin [15] and in this paper with histamine, AMPK is
partly activated independent of CaMKK and contributes to phosphor-
ylation of eNOS only under conditions that allow or facilitate an
agonist induced fall in cellular ATP (medium 199 or medium 1640
with added 2-deoxy-glucose). Furthermore, by using gene silencing of
LKB1 we show that the upstream AMPK kinase in this pathway is
indeed LKB1. Only when AMPK is activated by this LKB1 dependentFig. 5. The role of the two AMPKα isoforms in maintaining endothelial monolayer integrity
67 h). The effect of cotreatment with Tempol (10 μM). (B) The effect of siRNA for AMPKα1 an
(C) The effects of LKB1, AMPKα1 and/or−α2 siRNA (20 nM, 46 h) on ROS levels in HUVEC. T
siRNA (20 nM, 46 h) on the expression of p47phox in HUVEC. Cells were treated as described
control and show the average±S.D. of at least three independent experiments. The level of R
seven independent experiments each done in duplicate. (†ns/*pb0.01/**pb0.05 vs control,pathway does it contribute to the phosphorylation of eNOS (Fig. 4A).
After LKB1 downregulation there is marked reduction in NO-
production after histamine stimulation approaching the level ob-
served in cells maintained in medium 1640. In medium 1640 ATP is
not lowered after histamine stimulation and the LKB1-AMPK-eNOS
pathway is not activated. In LKB1 downregulated cells neither STO-
609 (an inhibitor of CaMKK and AMPK [21]) nor Compound C (an
inhibitor of AMPK) had any inhibitory effects on histamine mediated
eNOS phosphorylation demonstrating the dependence of the pathway
on LKB1.
In view of marked differences between the composition of the two
media, Morgan's 199 and RPMI 1640, we examined several possibil-
ities that could explain the different responses to stimulation in the
different media [15]. These included the presence of purines (ATP,
UTP, adenosine, xanthine and hypoxanthine), cholesterol and vita-
mins in medium 199 and their absence in medium 1640. However,
when the contribution of these ingredients had been excluded we
found a clear difference in ATP levels within cells after stimulation
depending on the presence of the non-ionic detergent tween 80 in the
medium. Adding tween 80 to medium 1640 in the miniscule amounts
(20 μg/mL) that are present in medium 199 resulted in a signiﬁcant
lowering of intracellular ATP after ionophore treatment and to a
similar activation of downstream pathways after thrombin treatment
(AMPK, ACC, eNOS phosphorylation) as in cells stimulated in medium
199 [15]. Addition of triton X-100, another non-ionic detergent, to
medium 1640, had similar effects as the addition of tween 80 (data. (A) A confocal image of HUVEC with or without siRNA for AMPKα1 or −α2 (20 nM,
d/or−α2 (20 nM, 46 h) on the expression of GRP78 and the effects of Tempol (10 μM).
he effect of cotreatment with Tempol (10 μM). (D) The effects of AMPKα1 and/or−α2
in Methods and results expressed as a ratio of GRP78:Actin or p47phox:Actin relative to
OSwasmeasured as described inMethods and the results expressed as average± S.D. of
††ns cells treated with AMPKα siRNA and Tempol vs cells treated with siRNA alone).
B C
D
Fig. 5 (continued).
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ATP fall after stimulation of HUVEC with ionophore, histamine or
thrombin although not affecting ATP in unstimulated cells.
Recently it was reported that although VEGF treatment of HUVEC
caused activation of AMPK as well as phosphorylation of eNOS at
Ser1177, the phosphorylation was not dependent on AMPK activity
[18]. Furthermore, AMPK did not phosphorylate eNOS even if the cells
were cotreated with 2-deoxy-glucose to lower ATP levels. These
results are in contrast to those previously reported by Reihill et al. [10]
who, based on the effects of dominant negative AMPK and
wortmannin, concluded that in human aortic endothelial cells both
AMPK and Akt contributed to eNOS phosphorylation and activation
after VEGF treatment. However, in contrast to our results with
histamine or thrombin, the AMPK contribution of eNOS phosphory-
lation in the VEGF treated cells was mediated only by CaMKK and not
by LKB1 as it was totally prevented by CaMKK siRNA. Martinelli et al.
recently reported that ICAM-1, which does not activate PI3K-Akt, also
causes AMPK-dependent eNOS phosphorylation via CaMKK in
microvascular endothelial cells [11].It has been suggested that phosphorylation of LKB1 at Ser428
facilitates activation of AMPK [33,34]. However, in melanocytes, this
phosphorylation was shown to prevent activation of AMPK by LKB1
[35,36]. In our study, we found that the treatment of HUVEC with
histamine or thrombin caused similar phosphorylation of LKB1 at
Ser428 in medium 199 and medium 1640 (Fig. 2D). Thus, differences
in LKB1 phosphorylation after stimulation cannot be invoked as an
explanation for the differences in eNOS phosphorylation in the two
media.
Although the α1 isoform is expressed to a greater extent in
endothelial cells than the α2 isoform [6,22] and it has even been
questionedwhether the latter is expressed in endothelial cells at all [37],
we previously found that both isoforms are present in primary cultures
of HUVEC and that both contribute to the phosphorylation of eNOS [15].
Furthermore, endothelial cells cultured from AMPKα2 knockout mice
have been found to produce much less NO after stimulation by Ca+2
ionophore than cells cultured from wild type mice [38].
Recently, Dong et al. found that the downregulation of AMPKα2
caused ER stress in HUVEC and although the α1 isoform was
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of AMPKα2 caused greater ER stress [22]. Although we ﬁnd that both
isoforms of AMPKα have to be downregulated to prevent eNOS
phosphorylation after either histamine or thrombin stimulation, we
observe that in medium 199 downregulation of α2 alone is sufﬁcient
to prevent ACC phosphorylation. Furthermore, in our study the stress
of serum removal produced almost instant morphologic changes in
conﬂuent monolayers of endothelial cells with downregulated
AMPKα2 but not in cells with downregulated AMPKα1 or LKB1.
These changes, involving shrinkage of cells with loss of intercellular
contacts and contact between cells and substrate, were markedly
inhibited or delayed by the SOD-mimetic Tempol. Downregulation of
AMPKα2, but notα1, also caused ER stress asmeasured by an increase
in GRP78 expression [39] and this increase was prevented by Tempol.
Downregulation of AMPKα2 caused an increase in ROS levels as
quantitated by DCF ﬂuorescence. However, in contrast to the
morphological changes and ER stress, the effect on ROS levels was
also observed in AMPKα1 downregulated cells and was not prevented
by Tempol. Colombo and Moncada have recently shown that α1
AMPK is a regulator of the antioxidant status of endothelial cells [40].
They observed that silencing of AMPKα1 in HUVEC caused a decrease
in the expression of genes involved in antioxidant defences, including
MnSOD, catalase and thioredoxin and an accumulation of ROS.
Regulation of antioxidant status by AMPK is also suggested by
increased levels of antioxidant enzymes by agents such as metformin
and AICAR which cause an increase in AMPK activity [41]. An increase
in ROS level could also result from an increase in production and
Wang et al. found increased expression of various components of
NADPH oxidase in AMPKα2 downregulated cells [42]. We, however,
did not observe any increase in the expression of gp91phox or p47phox
in our experiments. More work is needed to clarify the role of
AMPKα2 in maintaining endothelial monolayer integrity.
The demonstration of an LKB1-AMPK-eNOS signaling pathway in
endothelial cells adds one more element of complexity to eNOS
regulation (Fig. 6). It is of interest that environmental conditions
dictate which pathway is activated in response to external stimulationFig. 6. Diagram showing the proposed pathways after endothelial stimulation with
histamine or thrombin. Under conditions where intracellular ATP is lowered by
histamine or thrombin, AMPK is activated by both LKB1 and CaMKK and, in turn,
mediates eNOS phosphorylation and activation in an LKB1 dependent manner. Both
AMPKα1 and−α2 are involved in the signaling. Under conditions where intracellular
ATP is unchanged after histamine or thrombin treatment, CaMKK alone activates AMPK
and eNOS is phosphorylated and activated independent of AMPK.but even more so is the key role played by the cellular ATP level. A fall
in the cellular energy level is a well known consequence of pathologic
conditions such as ischemia, hypoxia and infection. AMPK-mediated
vasodilation through NOwould be one more example of how AMPK is
involved in the provision of energy at many levels of biological
organization [43].
In conclusion, we have shown that culture conditions affect
endothelial signal transduction pathways. Under conditions where
intracellular ATP is lowered by histamine, AMPK is activated by both
LKB1 and CaMKK and, in turn, mediates eNOS phosphorylation and
activation that is LKB1 dependent. Both the α1 and α2 isoforms of
AMPK are involved. Conversely, under conditions where intracellular
ATP is unchanged after histamine treatment, there is less NO-
production, activation of AMPK is only dependent on CaMKK and
eNOS is phosphorylated and activated independently of AMPK.
Furthermore, we also show that AMPKα2 is necessary for maintaining
integrity of the endothelial monolayer under the stress of serum
removal, and that downregulation of AMPKα2 but not AMPKα1
results in an increased expression of GRP78 which is indicative of ER
stress.
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